Geneart AG (ETR:G6A) is a Germany-based company engaged in the provision of integrated system solutions for deoxyribonucleic acid (DNA) engineering and processing in order to deliver improved drugs and biotech products. It is divided into three business areas: Red Biotechnology, active in the filed of protein drugs, deoxyribonucleic acid (DNA)-based drugs and recombinant vaccines; White Biotechnology, includes biocatalysts, and Green Biotechnology, engaged in production of biopharmaceuticals in plants and transgenic plants. Geneart's core business is gene synthesis and the production of artificial genes. Its spectrum of services includes gene optimization and synthesis, gene evolution services, and the development and manufacture of deoxyribonucleic acid (DNA)-based agents, including plasmid DNA. The Company is able to customize genes for specific customer applications with the GeneOptimizer Software used to model the properties of pharmaceutical and biotechnological products.
Geneart AG
FRA:G6A ISIN:DE000A0JJ4L4
News
Geneart AG (OJ:G6A) - Optimized synthetic standard genes are now also available for use in insect or mammalian cells
- The Deutsche Messe AG in Hannover (Germany) ranks the GENEART AG as one of the best European enterprises in biotechnology and life sciences - The exceptional innovative spirit combined with a high-performance business concept qualified the GENEART AG team for the final - The renowned biotechnology prize will be awarded on October 06, 2008 in Hannover
###
3,378 COMPANY PROFILE VIEWS
- This Page Viewed: (Last 7 Days: 12) (Last 30 Days: 48) (Since Published: 3378)